A New Take On New Year's And Chronic Weight Management: Smart Changes™ Program Combines Positive Lifestyle Changes With Prescription Medication For Weight Loss
Adults who are obese or overweightii who made
There is, however, some good news for people making weight loss and longer term weight management resolutions this year: 40 percent of those who made a
"People want to commit to healthier lifestyles at the New Year, but they often get trapped in a regular cycle of diet failure," said
Fortunately, people don't have to go it alone. The new Smart ChangesTM Program sponsored by
"The Smart Changes Program is designed to help people get the most out of their efforts," said
About the Survey
Survey results indicate that a comprehensive weight loss approach like the Smart Changes Program may fill an unmet need for obese and overweight people who unsuccessfully relied on OTC plans and who had difficulty making lifestyle changes for past
Among obese and overweight resolution-making adults, some of the most common reasons for failure were:
- Trouble following through on the plan (36 percent)
- Knowing what food choices to make but struggling to make healthier choices (33 percent)
- Feeling hungry all the time (28 percent)
Survey Methodology
This survey was conducted online within
About Smart Changes Program
Designed to help you make the most of your commitment to weight loss and longer term weight management, the Smart Changes Program combines positive lifestyle changes with a prescription medication proven to help you lose significant weight. It includes:
- A free 14-day trial of Qsymia® (phentermine and topiramate extended-release) capsules CIV, an
FDA -approved medication for the treatment of obesity - A free, limited, 3-month subscription to The Mayo Clinic Diet, including a daily meal planner, portion control guides, weight and habit trackers, food and fitness journal, more than 100 delicious recipes, and workout options.
The Mayo Clinic Diet is not a one-size-fits-all approach to weight loss. The
This limited free-trial offer does not represent an actual or implied endorsement of Qsymia by
About Qsymia
Qsymia is approved in the
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
About
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.
Media Relations:
Erin Guthrie
(212) 373-6052
i Classified as obese (BMI 30+) or overweight (BMI 27-29.9 and at least one comorbidity: hypertension/Type II diabetes/heart disease/sleep apnea/glucose intolerance/high cholesterol, high blood sugar, high triglycerides) |
ii Classified as obese (BMI 30+) or overweight (BMI 27-29.9 and at least one comorbidity: hypertension/Type II diabetes/heart disease/sleep apnea/glucose intolerance/high cholesterol, high blood sugar, high triglycerides) |
iii Or a weight loss effort starting in January |
iv OTC plan includes: popular diets, pre-packaged meals/ bars/shakes, OTC pills, vitamins/natural supplements, online or in person organized programs, changing diet and exercise habits on own |
v Or a weight loss effort starting in January |
vi Please note: base size for those who ever made a |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-new-take-on-new-years-and-chronic-weight-management-smart-changes-program-combines-positive-lifestyle-changes-with-prescription-medication-for-weight-loss-300190348.html
SOURCE
News Provided by Acquire Media